atorvastatin has been researched along with Granulomatosis with Polyangiitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bijl, M; de Leeuw, K; Kallenberg, CG; Limburg, PC; Souza, AW; Stegeman, CA; van Timmeren, MM; Westra, J | 1 |
| Abud-Mendoza, C; Baranda, L; Cruz-Rizo, J; Cuevas-Orta, E; de la Fuente, H; González-Amaro, R | 1 |
1 trial(s) available for atorvastatin and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; C-Reactive Protein; Child; Chloroquine; Dose-Response Relationship, Drug; Granulomatosis with Polyangiitis; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Proteinuria; Pyrroles; Rheumatic Diseases; Rheumatic Fever; Simvastatin; Treatment Outcome | 2003 |
1 other study(ies) available for atorvastatin and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.
Topics: Atherosclerosis; Atorvastatin; Female; Granulomatosis with Polyangiitis; Heptanoic Acids; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prednisolone; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Solubility | 2014 |